Aduro BioTech Garners $55,000,000 Series C Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=286ee989-7f2c-4cd8-904c-66dca9f4f733
Date
6/12/2014
Company Name
Aduro BioTech
Mailing Address
626 Bancroft Way Berkeley, CA 94710 USA
Company Description
Aduro BioTech is a clinical-stage immunotherapy company with a platform technology for therapeutic and prophylactic vaccines for cancer and infectious diseases. The platform of attenuated and targeted vaccines based on Listeria monocytogenes has been in development for nine years.
Website
http://www.adurobiotech.com
Transaction Type
Venture Equity
Transaction Amount
$55,000,000
Transaction Round
Series C
Proceeds Purposes
Aduro plans to use the new capital to advance its lead program in metastatic pancreatic cancer through its ongoing Phase 2b ECLIPSE clinical trial, to continue clinical development in mesothelioma and high-grade glioma, to expand into additional indications and to advance its small molecule program targeting the immunomodulatory STING receptor.
M&A Terms
Venture Investor
Venture Investor
Venture Investor